Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuichiro Shirai

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|January 22, 2015
Reply: To PMID 25385504Yuichiro Shirai, Masataka Kuwana
The Lancet. Rheumatology|April 3, 2025
Is type I interferon score a promising circulating biomarker for systemic sclerosis?Yuichiro Shirai, Masataka Kuwana
The Journal of Rheumatology|August 3, 2016
Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung DiseaseMasataka Kuwana, Yuichiro Shirai, Tsutomu Takeuchi
Rheumatology (Oxford, England)|March 8, 2022
Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in JapanYohei Isomura, Yuichiro Shirai, Masataka Kuwana
Rheumatology (Oxford, England)|July 24, 2020
Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-associated interstitial lung diseaseTakashi Nawata, Yuichiro Shirai, Mikito Suzuki, et al.
Journal of Scleroderma and Related Disorders|April 7, 2022
Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosisYuichiro Shirai, Noriyuki Kawami, Katsuhiko Iwakiri, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung DiseaseYuichiro Shirai, Ryosuke Fukue, Yuko Kaneko, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|September 15, 2017
Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue DiseaseHidekata Yasuoka, Yuichiro Shirai, Yuichi Tamura, et al.
The European Respiratory Journal|January 18, 2014
IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatmentYuichiro Shirai, Yuichi Tamura, Hidekata Yasuoka, et al.
Modern Rheumatology|January 30, 2013
Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single centerYuichiro Shirai, Hidekata Yasuoka, Tsutomu Takeuchi, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Arthritis & Rheumatology (Hoboken, N.J.)|January 22, 2015
Reply: To PMID 25385504Yuichiro Shirai, Masataka Kuwana
The Lancet. Rheumatology|April 3, 2025
Is type I interferon score a promising circulating biomarker for systemic sclerosis?Yuichiro Shirai, Masataka Kuwana
The Journal of Rheumatology|August 3, 2016
Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung DiseaseMasataka Kuwana, Yuichiro Shirai, Tsutomu Takeuchi
Rheumatology (Oxford, England)|March 8, 2022
Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in JapanYohei Isomura, Yuichiro Shirai, Masataka Kuwana
Rheumatology (Oxford, England)|July 24, 2020
Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-associated interstitial lung diseaseTakashi Nawata, Yuichiro Shirai, Mikito Suzuki, et al.
Journal of Scleroderma and Related Disorders|April 7, 2022
Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosisYuichiro Shirai, Noriyuki Kawami, Katsuhiko Iwakiri, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung DiseaseYuichiro Shirai, Ryosuke Fukue, Yuko Kaneko, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|September 15, 2017
Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue DiseaseHidekata Yasuoka, Yuichiro Shirai, Yuichi Tamura, et al.
The European Respiratory Journal|January 18, 2014
IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatmentYuichiro Shirai, Yuichi Tamura, Hidekata Yasuoka, et al.
Modern Rheumatology|January 30, 2013
Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single centerYuichiro Shirai, Hidekata Yasuoka, Tsutomu Takeuchi, et al.
Pageof 4